Cardiff Oncology, Inc. (NASDAQ:CRDF) Q2 2024 Earnings Call Transcript
Operator: Welcome to the Cardiff Oncology Second Quarter 2024 Financial Results and Business Update Conference Call.
Cardiff Oncology Inc. (CRDF)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Renaissance Technologies Jim Simons | 602,384 | $1,608,365 | +283% | 0% |
| 2. | Two Sigma Advisors John Overdeck And David Siegel | 331,200 | $884,304 | +60% | 0% |
| 3. | Millennium Management Israel Englander | 152,685 | $407,669 | -37% | 0% |
| 4. | Marshall Wace LLP Paul Marshall And Ian Wace | 143,026 | $381,880 | -53% | 0% |
| 5. | Citadel Investment Group Ken Griffin | 50,546 | $134,958 | -10% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $5.00 | 2,400 | 67,716 | 2024-12-18 | Filing | ||
| $5.42 | 2,752 | 65,316 | 2024-12-17 | Filing | ||
| $3.83 | 2,564 | 62,564 | 2024-12-16 | Filing | ||
| $3.42 | 10,000 | 20,000 | 2024-12-12 | Filing | ||
| $2.60 | 11,500 | 1,059,376 | 2024-12-11 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $18.60 | 35,321 | Officer | 5,054 | 2020-11-23 | Filing | |
| $0.69 | 8,334 | Director | 209,394 | 2017-09-05 | Filing | |
| $8.64 | 4,200 | Director | 326,486 | 2013-09-03 | Filing | |
| $8.06 | 15,000 | Director | 330,686 | 2013-08-30 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 1,911,789 | $2,829,448 | 0% | |
| 2. | 716,490 | $1,060,406 | 0% | |
| 3. | 424,106 | $627,823 | 0% | |
| 4. | 379,310 | $561,379 | 0% | |
| 5. | 139,945 | $207,119 | 0% |
News See All
Cardiff Oncology, Inc. (NASDAQ:CRDF) Q1 2023 Earnings Call Transcript
Operator: Welcome to the Cardiff Oncology First Quarter 2024 Financial Results and Business Update Conference Call. At this time, all participants are in a listen-only mode.
Cardiff Oncology, Inc. (NASDAQ:CRDF) Q4 2023 Earnings Call Transcript
Cardiff Oncology, Inc. beats earnings expectations. Reported EPS is $-0.21, expectations were $-0.26.
Cardiff Oncology, Inc. (NASDAQ:CRDF) Q3 2023 Earnings Call Transcript
Operator: Welcome to the Cardiff Oncology third-quarter 2023 financial results and corporate update conference call. [Operator Instructions].
Hedge Fund and Insider Trading News: John Paulson, Michael Burry, Mike Novogratz, Paul Singer, Bluebell Capital Partners, Tiger Global Management, ExodusPoint Capital, Crowdstrike Holdings Inc (CRWD), aTyr Pharma Inc (LIFE), and More
Billionaire crypto investor Mike Novogratz has said bitcoin holding firm at $40,000 during the recent sell-off is a good sign for the market, and recommended buying the dip in digital assets.
Hedge Funds Have Never Been This Bullish On Cardiff Oncology (CRDF)
At Insider Monkey, we pore over the filings of nearly 817 top investment firms every quarter, a process we have now completed for the latest reporting period.
Billionaire Hedge Funds
